As expected by many investors and the lead physicians, the Phase I trial continues to show promising results with no significant toxicity. Results were reported today and are listed in the news column on this page. The plan will be to test even higher doses in phase I study, since they are not limited by toxicity (so far). Phase II study plans are being expanded as well and this drug could be submitted for approval before the end of 2013. The only surprise is that we can still buy this stock for .35. That cannot last much longer.
Agreed, BPTH remains way under-valued in my opinion. Probably won't have a significant price movement until the Phase II trial is approved tho, so in the mean time I'll be buying on the dips whenever I can.